EchoGo-guided alerts to identify and prevent heart failure in people with type 2 diabetes
Official title: Identifying Undiagnosed HFpEF Among Patients With Type 2 Diabetes Using Ultromics AI HFpEF Algorithm
Run by University of Texas Southwestern Medical Center · NCT06593314 · Data updated 2026-11-12
This project will test if giving doctors EchoGo algorithm results and EHR alerts leads to more guideline-recommended heart-failure prevention treatment for people with type 2 diabetes who show signs of HFpEF on a recent echocardiogram.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 800 (estimated) |
| Sponsor | University of Texas Southwestern Medical Center Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Status | Recruiting |
| Started | August 6, 2025 |
| Main results expected | May 15, 2027 |
| Study ends | July 15, 2027 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT06593314 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with type 2 diabetes who have a recent (within 6 months) echocardiogram in the UT Southwestern EHR, a high WATCH DM score, no prior history of heart failure, and who are eligible for new SGLT2i, GLP-1RA or ns‑MRA therapy.
✕Probably not a fit
Patients with prior heart failure, those without a recent echocardiogram in the system, or those who are not eligible for the recommended medications are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Historic echocardiograms in the UT Southwestern EHR will be reanalyzed using the Ultromics EchoGo algorithm to identify subclinical HFpEF among patients with type 2 diabetes and a high WATCH DM score. Providers for patients with a positive EchoGo result will be randomized to receive either an EHR-based clinical decision support alert with EchoGo findings and guideline-based recommendations (including SGLT2i, non‑steroidal MRA, or GLP‑1 RA when appropriate) or a standard message. Investigators will track provider prescribing and care patterns at 3 and 6 months and will monitor downstream heart-failure hospitalizations for 12 months after the alert. The design is pragmatic and embedded in routine clinical workflows to measure real-world impact on prevention care and short-term clinical outcomes.
Why it matters
Potential benefit: If successful, this approach could lead to earlier initiation of guideline therapies and reduce heart-failure hospitalizations in people with type 2 diabetes.
How similar studies have gone: SGLT2 inhibitors, GLP‑1 receptor agonists, and non‑steroidal MRAs have shown benefits for heart-failure outcomes, but using automated EchoGo imaging analysis combined with EHR provider alerts to change prescribing behavior is relatively novel with limited prior trial data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Clinical cohort inclusion exclusion criteria: Inclusion Criteria: * Patients with diagnosis of Type 2 diabetes and High WATCH DM score. * Echocardiogram available in last 6-months. Exclusion Criteria: * History of HF * Not eligible for prescription of new GLP-1RA or SGLT2i or ns-MRA Corresponding providers to patients identified by the above inclusion exclusion criteria will be included in the clinical trial of the decision support tool.
Where it's running
-
UT Southwestern Medical Center
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Ambarish Pandey, MD — University of Texas Southwestern Medical Center
- Study coordinator: Ambarish Pandey, MD
- Email: Ambarish.Pandey@UTSouthwestern.edu
- Phone: 617-869-8957
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Somatic health screening for adults in psychiatric outpatient care
This program tries adding regular physical-health screening into psychiatric outpatient care to see if it helps detect and manage heart disease, lung disease, diabetes, and other conditions in adults with psychotic or affective disorders.
-
Validating lab assays, IV catheter techniques, and devices for endocrine, cardiometabolic, and musculoskeletal conditions
This project will test whether laboratory assays, IV catheter methods, and equipment give consistent, reliable results in adults with or without obesity-related, metabolic, or musculoskeletal conditions.
-
Assessing arterial stiffness and heart disease risk using a novel technology
This study is testing a new, no-touch technology to measure how stiff your arteries are and see if it can help figure out your risk for heart disease.
-
Using Apple Watch data to predict heart failure outcomes
This study is testing if data from Apple Watches can help predict heart failure problems and the chances of needing to go back to the hospital for patients with heart failure.
-
App to support post-hospital care for people with multiple chronic conditions
This trial will test a smartphone/tablet app to help people aged 55+ with heart failure, diabetes, or chronic kidney disease manage their care after leaving the hospital.
-
Comparing Aortix Device to Diuretics for Acute Heart Failure
This study is testing whether the Aortix device can help people with acute heart failure who aren't responding to diuretics feel better compared to standard treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.